Sarepta Therapeutics Stock Plummets After Q1 Results: Here's Why - Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics Stock Plummets After Q1 Results: Here's Why - Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shares are sinking after the company released its first-quarter results after Tuesday's closing bell. Here's a look at the details from the report.  The Details: Sarepta Therapeutics reported quarterly losses of $3.42 per share, which missed the analyst consensus estimate of losses of 95 cents. Quarterly revenue came in at $744.86 million, which beat the consensus estimate of $683.36 million. Read Next:  …

Moderna, Sarepta Puke After FDA Names Vinay Prasad As Vaccines, Biologics Head

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

Moderna, Sarepta Puke After FDA Names Vinay Prasad As Vaccines, Biologics Head – altnews.org

Vaccine and immunotherapies companies tumbled during the afternoon cash session in New York after FDA Commissioner Marty Makary named Vinay